-
Mashup Score: 3From IMPERIALism to EMINENence: The Noble Rise of the Second-Generation Peripheral Drug-Eluting Stent - 1 year(s) ago
Eric A. Secemsky Correspondence to: Eric A. Secemsky, MD, MSc, Director of Vascular Intervention, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, 4th Floor, Boston, MA 02215. Email E-mail Address: [email protected] https://orcid.org/0000-0003-3861-3163 Harvard Medical School, Boston, MA (E.A.S.). Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology and Division of…
Source: CirculationCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
BACKGROUND: A clear patency benefit of a drug-eluting stent (DES) over a bare metal stent (BMS) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonst
Source: CirculationCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr. Yann Gouëffic presented included 1-year results from the EMINENT trial of 775 patients, making it the largest randomized industrial trial of a drug-eluting stent for the treatment of peripheral arterial disease to date.
Source: HMP Global Learning NetworkCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr. Yann Gouëffic presented included 1-year results from the EMINENT trial of 775 patients, making it the largest randomized industrial trial of a drug-eluting stent for the treatment of peripheral arterial disease to date.
Source: HMP Global Learning NetworkCategories: Cardiology News and Journals, Latest HeadlinesTweet
#Editorial DES v. BMS for symptomatic fem-pop bypass #EMINENT RCT #PAD #AHAJournals @EricSecemskyMD https://t.co/rQYstwnV8l https://t.co/vqFZyjiYVU